Ana Martinez

List of Publications by Citations

302 papers	9,320 citations	52 h-index	82 g-index
341 ext. papers	10,541 ext. citations	5.3 avg, IF	6.15 L-index

#	Paper	IF	Citations
302	First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. *Journal of Medicinal Chemistry*, **2002**, 45, 1292-9	8.3	383
301	Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. *Medicinal Research Reviews*, **2002**, 22, 373-84	14.4	275
300	GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS. *Frontiers in Molecular Neuroscience*, **2011**, 4, 32	6.1	225
299	Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. *Journal of Medicinal Chemistry*, **2006**, 49, 459-62	8.3	223
298	Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties. *Journal of Medicinal Chemistry*, **2010**, 53, 4927-37	8.3	218
297	New tacrine-4-oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer's disease, with cholinergic, antioxidant, and β-amyloid-reducing properties. *Journal of Medicinal Chemistry*, **2012**, 55, 1303-17	8.3	211
296	COVID-19: Drug Targets and Potential Treatments. *Journal of Medicinal Chemistry*, **2020**, 63, 12359-12386	8.3	207
295	Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease. *Journal of Medicinal Chemistry*, **2005**, 48, 7223-33	8.3	179
294	Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. *Current Pharmaceutical Design*, **2006**, 12, 4377-87	3.3	167
293	Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. *Journal of Biological Chemistry*, **2005**, 280, 21453-62	5.4	155
292	Tacrine-melatonin hybrids as multifunctional agents for Alzheimer's disease, with cholinergic, antioxidant, and neuroprotective properties. *ChemMedChem*, **2009**, 4, 828-41	3.7	132
291	Donepezil-tacrine hybrid related derivatives as new dual binding site inhibitors of AChE. *Bioorganic and Medicinal Chemistry*, **2005**, 13, 6588-97	3.4	129
290	Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease. *Mini-Reviews in Medicinal Chemistry*, **2001**, 1, 267-72	3.2	116
289	Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease. *Journal of Natural Products*, **2007**, 70, 1397-405	4.9	110
288	Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases. *Journal of Natural Products*, **2006**, 69, 1034-40	4.9	110
287	Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo. *ACS Chemical Neuroscience*, **2012**, 3, 963-71	5.7	108
286	Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2008**, 32, 1549-56	5.5	105

285	GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease?. *Journal of Alzheimerjs Disease*, **2008**, 15, 181-91	4.3	105
284	SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors. *Journal of Medicinal Chemistry*, **2005**, 48, 7103-12	8.3	102
283	Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors. *Medicinal Research Reviews*, **2005**, 25, 229-44	14.4	100
282	Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases. *Medicinal Research Reviews*, **2011**, 31, 924-54	14.4	98
281	Thienyl and phenyl alpha-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-3beta) from a library of compound searching. *Journal of Medicinal Chemistry*, **2003**, 46, 4631-3	8.3	92
280	Stress-induced neuroinflammation is mediated by GSK3-dependent TLR4 signaling that promotes susceptibility to depression-like behavior. *Brain, Behavior, and Immunity*, **2016**, 53, 207-222	16.6	91
279	Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice. *Biological Psychiatry*, **2014**, 75, 198-206	7.9	91
278	NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders. *Journal of Neuroscience*, **2007**, 27, 5766-76	6.6	91
277	Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3 inhibitors. *Angewandte Chemie - International Edition*, **2015**, 54, 1578-82	16.4	87
276	TNF disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice. *Brain, Behavior, and Immunity*, **2018**, 69, 556-567	16.6	87
275	Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease. *Journal of Medicinal Chemistry*, **2009**, 52, 7249-57	8.3	85
274	Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs. *Medicinal Research Reviews*, **2008**, 28, 773-96	14.4	84
273	Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities. *Journal of Medicinal Chemistry*, **2011**, 54, 8461-70	8.3	78
272	Reduction of body weight, liver steatosis and expression of stearoyl-CoA desaturase 1 by the isoflavone daidzein in diet-induced obesity. *British Journal of Pharmacology*, **2011**, 164, 1899-915	8.6	76
271	Versatility of the Curcumin Scaffold: Discovery of Potent and Balanced Dual BACE-1 and GSK-3 Inhibitors. *Journal of Medicinal Chemistry*, **2016**, 59, 531-44	8.3	73
270	N-Benzylpiperidine derivatives of 1,2,4-thiadiazolidinone as new acetylcholinesterase inhibitors. *European Journal of Medicinal Chemistry*, **2000**, 35, 913-22	6.8	73
269	Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis. *Journal of Medicinal Chemistry*, **2014**, 57, 2755-72	8.3	70
268	New melatonin-N,N-dibenzyl(N-methyl)amine hybrids: potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease. *Journal of Medicinal Chemistry*, **2014**, 57, 3773-85	8.3	70

267	Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease. *Expert Opinion on Investigational Drugs*, **2006**, 15, 1-12	5.9	70
266	Phosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson disease. *PLoS ONE*, **2011**, 6, e17240	3.7	69
265	Nitric oxide in the cerebral cortex of amyloid-precursor protein (SW) Tg2576 transgenic mice. *Neuroscience*, **2004**, 128, 73-89	3.9	65
264	Benzyl derivatives of 2,1,3-benzo- and benzothieno[3,2-a]thiadiazine 2,2-dioxides: first phosphodiesterase 7 inhibitors. *Journal of Medicinal Chemistry*, **2000**, 43, 683-9	8.3	65
263	Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease. *Neurobiology of Aging*, **2013**, 34, 2133-45	5.6	64
262	GSK-3 inhibitors: discoveries and developments. *Current Medicinal Chemistry*, **2004**, 11, 755-63	4.3	62
261	5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3. *Journal of Medicinal Chemistry*, **2012**, 55, 1645-61	8.3	61
260	Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment. *International Journal of Alzheimerjs Disease*, **2011**, 2011, 280502	3.7	60
259	Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds. *Journal of Medicinal Chemistry*, **2011**, 54, 4042-56	8.3	60
258	cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases. *Expert Opinion on Therapeutic Patents*, **2014**, 24, 1311-21	6.8	59
257	Regulation of Th1 cells and experimental autoimmune encephalomyelitis by glycogen synthase kinase-3. *Journal of Immunology*, **2013**, 190, 5000-11	5.3	58
256	Synthesis, biological assessment, and molecular modeling of racemic 7-aryl-9,10,11,12-tetrahydro-7H-benzo[7,8]chromeno[2,3-b]quinolin-8-amines as potential drugs for the treatment of Alzheimer's disease. *European Journal of Medicinal Chemistry*, **2012**, 54, 750-63	6.8	55
255	Tau-Centric Multitarget Approach for Alzheimer's Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3 and Tau-Aggregation Inhibitors. *Journal of Medicinal Chemistry*, **2018**, 61, 7640-7656	8.3	53
254	Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model. *European Journal of Medicinal Chemistry*, **2012**, 47, 175-85	6.8	53
253	Synthesis, structural analysis, and biological evaluation of thioxoquinazoline derivatives as phosphodiesterase 7 inhibitors. *ChemMedChem*, **2009**, 4, 866-76	3.7	53
252	Phosphodiesterase inhibitory properties of losartan. Design and synthesis of new lead compounds. *Bioorganic and Medicinal Chemistry Letters*, **1998**, 8, 505-10	2.9	53
251	Non-ATP competitive glycogen synthase kinase 3beta (GSK-3beta) inhibitors: study of structural requirements for thiadiazolidinone derivatives. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 495-510	3.4	53
250	PDE 7 inhibitors: new potential drugs for the therapy of spinal cord injury. *PLoS ONE*, **2011**, 6, e15937	3.7	52

249	Tautomerism and acidity in 4-quinolone-3-carboxylic acid derivatives. *Tetrahedron*, **1992**, 48, 6135-6150	2.4	51
248	3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3 Fragment Hits against Alzheimer's Disease. *ACS Chemical Neuroscience*, **2015**, 6, 1665-82	5.7	47
247	Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease. *ACS Chemical Neuroscience*, **2013**, 4, 350-60	5.7	47
246	Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. *European Journal of Medicinal Chemistry*, **2013**, 60, 479-89	6.8	47
245	Inhibitors of glycogen synthase kinase-3: future therapy for unmet medical needs?. *Expert Opinion on Therapeutic Patents*, **2002**, 12, 1527-1536	6.8	47
244	N-methylamino-l-alanine causes neurological and pathological phenotypes mimicking Amyotrophic Lateral Sclerosis (ALS): the first step towards an experimental model for sporadic ALS. *Environmental Toxicology and Pharmacology*, **2013**, 36, 243-255	5.8	46
243	Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 6914-25	3.4	44
242	CoMFA of benzyl derivatives of 2,1,3-benzo and benzothieno[3,2-alpha]thiadiazine 2,2-dioxides: clues for the design of phosphodiesterase 7 inhibitors. *European Journal of Medicinal Chemistry*, **2001**, 36, 333-8	6.8	44
241	Amyloid induced impairments on mitochondrial dynamics, hippocampal neurogenesis, and memory are restored by phosphodiesterase 7 inhibition. *Alzheimerjs Research and Therapy*, **2018**, 10, 24	9	43
240	Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds. *Journal of Medicinal Chemistry*, **2012**, 55, 3274-84	8.3	43
239	Pyridonepezils, new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease: synthesis, biological assessment, and molecular modeling. *European Journal of Medicinal Chemistry*, **2012**, 57, 296-301	6.8	43
238	Design and synthesis of N-benzylpiperidine-purine derivatives as new dual inhibitors of acetyl- and butyrylcholinesterase. *Bioorganic and Medicinal Chemistry*, **2005**, 13, 6795-802	3.4	43
237	N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease. *European Journal of Medicinal Chemistry*, **2011**, 46, 2224-35	6.8	42
236	Inhibition of endogenous phosphodiesterase 7 promotes oligodendrocyte precursor differentiation and survival. *Cellular and Molecular Life Sciences*, **2013**, 70, 3449-62	10.3	39
235	Synthesis, pharmacological assessment, and molecular modeling of acetylcholinesterase/butyrylcholinesterase inhibitors: effect against amyloid-induced neurotoxicity. *ACS Chemical Neuroscience*, **2013**, 4, 547-65	5.7	39
234	Old phenothiazine and dibenzothiadiazepine derivatives for tomorrow's neuroprotective therapies against neurodegenerative diseases. *European Journal of Medicinal Chemistry*, **2010**, 45, 6152-8	6.8	39
233	Comparative assessment of PDE 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis. *British Journal of Pharmacology*, **2013**, 170, 602-13	8.6	38
232	Potent beta-amyloid modulators. *Neurodegenerative Diseases*, **2008**, 5, 153-6	2.3	38

231	Targeting TDP-43 phosphorylation by Casein Kinase-1 inhibitors: a novel strategy for the treatment of frontotemporal dementia. *Molecular Neurodegeneration*, **2016**, 11, 36	19	37
230	PDE7 inhibitors as new drugs for neurological and inflammatory disorders. *Expert Opinion on Therapeutic Patents*, **2008**, 18, 1127-1139	6.8	37
229	New cinnamic - N-benzylpiperidine and cinnamic - N,N-dibenzyl(N-methyl)amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties. *European Journal of Medicinal Chemistry*, **2016**, 121, 376-386	6.8	37
228	Subtly Modulating Glycogen Synthase Kinase 3 Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases. *Journal of Medicinal Chemistry*, **2017**, 60, 4983-5001	8.3	36
227	A Fluorescent Styrylquinoline with Combined Therapeutic and Diagnostic Activities against Alzheimer's and Prion Diseases. *ACS Medicinal Chemistry Letters*, **2013**, 4, 225-9	4.3	36
226	Dual inhibitor of PDE7 and GSK-3-VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice. *Neuropharmacology*, **2013**, 64, 205-14	5.5	36
225	From dual binding site acetylcholinesterase inhibitors to allosteric modulators: A new avenue for disease-modifying drugs in Alzheimer's disease. *European Journal of Medicinal Chemistry*, **2017**, 139, 773-791	6.8	35
224	Inhibition of tau phosphorylation: a new therapeutic strategy for the treatment of Alzheimer disease and other neurodegenerative disorders. *Expert Opinion on Therapeutic Patents*, **2000**, 10, 1519-1527	6.8	34
223	Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease. *European Journal of Medicinal Chemistry*, **2014**, 73, 56-72	6.8	33
222	Polyaniline-based microelectrodes for sensing ascorbic acid in beverages. *Current Applied Physics*, **2008**, 8, 320-323	2.6	32
221	Novel Triazole-Quinoline Derivatives as Selective Dual Binding Site Acetylcholinesterase Inhibitors. *Molecules*, **2016**, 21,	4.8	32
220	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015). *Expert Opinion on Therapeutic Patents*, **2017**, 27, 657-666	6.8	31
219	GSK-3 inhibitor TDZD-8 reduces neonatal hypoxic-ischemic brain injury in mice. *CNS Neuroscience and Therapeutics*, **2017**, 23, 405-415	6.8	30
218	Phosphodiesterase 7 inhibition induces dopaminergic neurogenesis in hemiparkinsonian rats. *Stem Cells Translational Medicine*, **2015**, 4, 564-75	6.9	30
217	CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example. *European Journal of Medicinal Chemistry*, **2008**, 43, 1349-59	6.8	29
216	CODES/Neural Network Model: a Useful Tool for in Silico Prediction of Oral Absorption and Blood-Brain Barrier Permeability of Structurally Diverse Drugs. *QSAR and Combinatorial Science*, **2004**, 23, 89-98		29
215	Synthesis and potential muscarinic receptor binding and antioxidant properties of 3-(thiadiazolyl)pyridine 1-oxide compounds. *Archiv Der Pharmazie*, **1999**, 332, 191-4	4.3	29
214	Phosphodiesterase7 Inhibition Activates Adult Neurogenesis in Hippocampus and Subventricular Zone In Vitro and In Vivo. *Stem Cells*, **2017**, 35, 458-472	5.8	28

213	Dual binding site acetylcholinesterase inhibitors: potential new disease-modifying agents for AD. *Journal of Molecular Neuroscience*, **2006**, 30, 85-8	3.3	28
212	Non-cholinergic pharmacotherapy approaches to the future treatment of Alzheimer's disease. *Mini-Reviews in Medicinal Chemistry*, **2002**, 2, 37-50	3.2	28
211	Lessons learnt from glycogen synthase kinase 3 inhibitors development for Alzheimer's disease. *Current Topics in Medicinal Chemistry*, **2013**, 13, 1808-19	3	28
210	Tideglusib, a chemical inhibitor of GSK3attenuates hypoxic-ischemic brain injury in neonatal mice. *Biochimica Et Biophysica Acta - General Subjects*, **2016**, 1860, 2076-85	4	28
209	Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis. *Scientific Reports*, **2017**, 7, 43545	4.9	27
208	Interference of the complex between NCS-1 and Ric8a with phenothiazines regulates synaptic function and is an approach for fragile X syndrome. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E999-E1008	11.5	26
207	Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease. *European Journal of Medicinal Chemistry*, **2018**, 156, 534-553	6.8	26
206	O-Pyrazolylpropynyl-Hydroxylamines as Versatile Intermediates in the Synthesis of Compounds of Pharmacological Interest. *Synthesis*, **2001**, 2001, 1711-1715	2.9	26
205	Recent strategies in the development of new human cytomegalovirus inhibitors. *Medicinal Research Reviews*, **2001**, 21, 227-44	14.4	25
204	The problem of the existence of C(Ar)H ? N intramolecular hydrogen bonds in a family of 9-azaphenyl-9H-carbazoles. *Journal of the Chemical Society Perkin Transactions II*, **1993**, 1547-1555		25
203	Synthesis, pharmacological assessment, and molecular modeling of 6-chloro-pyridonepezils: new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease. *European Journal of Medicinal Chemistry*, **2013**, 67, 64-74	6.8	24
202	Silencing phosphodiesterase 7B gene by lentiviral-shRNA interference attenuates neurodegeneration and motor deficits in hemiparkinsonian mice. *Neurobiology of Aging*, **2015**, 36, 1160-73	5.6	24
201	Benzothiazepine CGP37157 and its isosteric 2'-methyl analogue provide neuroprotection and block cell calcium entry. *ACS Chemical Neuroscience*, **2012**, 3, 519-29	5.7	24
200	The potential role of glycogen synthase kinase 3 inhibitors as amyotrophic lateral sclerosis pharmacological therapy. *Current Medicinal Chemistry*, **2011**, 18, 3028-34	4.3	24
199	Benzothiadiazine dioxide dibenzyl derivatives as potent human cytomegalovirus inhibitors: synthesis and comparative molecular field analysis. *Journal of Medicinal Chemistry*, **2000**, 43, 3218-25	8.3	24
198	Application of BACE1 immobilized enzyme reactor for the characterization of multifunctional alkaloids from Corydalis cava (Fumariaceae) as Alzheimer's disease targets. *Fitoterap***2016**, 109, 241-7	3.2	23
197	Nonnucleoside human cytomegalovirus inhibitors: synthesis and antiviral evaluation of (chlorophenylmethyl)benzothiadiazine dioxide derivatives. *Journal of Medicinal Chemistry*, **2000**, 43, 3267-73	8.3	23
196	Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1 kinase inhibitor treatment. *Scientific Reports*, **2020**, 10, 4449	4.9	22

195	New neurogenic lipoic-based hybrids as innovative Alzheimer's drugs with 1 agonism and secretase inhibition. *Future Medicinal Chemistry*, **2016**, 8, 1191-207	4.1	22
194	A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation. *European Journal of Medicinal Chemistry*, **2012**, 48, 206-13	6.8	22
193	An application of two MIFs-based tools (Volsurf+ and Pentacle) to binary QSAR: the case of a palinurin-related data set of non-ATP competitive glycogen synthase kinase 3 (GSK-3) inhibitors. *European Journal of Medicinal Chemistry*, **2011**, 46, 860-9	6.8	22
192	The first enantioselective synthesis of palinurin. *Chemical Communications*, **2009**, 3252-4	5.8	22
191	A 1H and 13c Nmr study of the structure and tautomerism of 4-pyrazolylpyrazolinones. *Journal of Heterocyclic Chemistry*, **1990**, 27, 865-870	1.9	22
190	Identification of new allosteric sites and modulators of AChE through computational and experimental tools. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2018**, 33, 1034-1047	5.6	21
189	Neuroprotective effect of the new thiadiazolidinone NP00111 against oxygen-glucose deprivation in rat hippocampal slices: implication of ERK1/2 and PPARgamma receptors. *Experimental Neurology*, **2008**, 212, 93-9	5.7	21
188	Marine compounds for the therapeutic treatment of neurological disorders. *Expert Opinion on Therapeutic Patents*, **2005**, 15, 1377-1386	6.8	21
187	Novel potential agents for human cytomegalovirus infection: synthesis and antiviral activity evaluation of benzothiadiazine dioxide acyclonucleosides. *Journal of Medicinal Chemistry*, **1999**, 42, 1145-50	8.3	21
186	Development of Blood-Brain Barrier Permeable Nitrocatechol-Based Catechol O-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity. *Journal of Medicinal Chemistry*, **2016**, 59, 7584-97	8.3	21
185	Neurogenic Potential Assessment and Pharmacological Characterization of 6-Methoxy-1,2,3,4-tetrahydro-carboline (Pinoline) and Melatonin-Pinoline Hybrids. *ACS Chemical Neuroscience*, **2015**, 6, 800-10	5.7	20
184	5-Imino-1,2-4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3 (GSK-3) and phosphodiesterase 7 (PDE7) inhibitors: determination of blood-brain barrier penetration and binding to human serum albumin. *European Journal of Pharmaceutical Sciences*, **2012**, 45, 677-84	5.1	20
183	Medicinal and Biological Chemistry (MBC) Library: An Efficient Source of New Hits. *Journal of Chemical Information and Modeling*, **2017**, 57, 2143-2151	6.1	20
182	PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis. *British Journal of Pharmacology*, **2015**, 172, 4277-90	8.6	19
181	Design, synthesis, and evaluation of potential inhibitors of nitric oxide synthase. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 6193-206	3.4	19
180	Phosphodiesterase 10 inhibitors: new disease modifying drugs for Parkinson's disease?. *Current Medicinal Chemistry*, **2014**, 21, 1171-87	4.3	19
179	Highly potent and selective aryl-1,2,3-triazolyl benzylpiperidine inhibitors toward butyrylcholinesterase in Alzheimer's disease. *Bioorganic and Medicinal Chemistry*, **2019**, 27, 931-943	3.4	19
178	The GSK-3-inhibitor VP2.51 produces antidepressant effects associated with adult hippocampal neurogenesis. *Neuropharmacology*, **2017**, 116, 174-187	5.5	18

177	New flavonoid - ,-dibenzyl(-methyl)amine hybrids: Multi-target-directed agents for Alzheimer's disease endowed with neurogenic properties. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2019**, 34, 712-727	5.6	18
176	1-(Benzo[d]thiazol-2-yl)-3-phenylureas as dual inhibitors of casein kinase 1 and ABAD enzymes for treatment of neurodegenerative disorders. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2018**, 33, 665-670	5.6	18
175	Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors. *Journal of Medicinal Chemistry*, **2014**, 57, 8590-607	8.3	18
174	Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice. *ACS Chemical Neuroscience*, **2012**, 3, 793-803	5.7	18
173	Arylimino-1,2,4-thiadiazolidinones: a new family of potassium channel openers. *Bioorganic and Medicinal Chemistry*, **1997**, 5, 1275-83	3.4	18
172	From Bitopic Inhibitors to Multitarget Drugs for the Future Treatment of Alzheimer's Disease. *Current Medicinal Chemistry*, **2015**, 22, 3789-806	4.3	18
171	Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia. *European Journal of Medicinal Chemistry*, **2017**, 130, 60-72	6.8	17
170	Correction of Glycogen Synthase Kinase 3 in Myotonic Dystrophy 1 Reduces the Mutant RNA and Improves Postnatal Survival of DMSXL Mice. *Molecular and Cellular Biology*, **2019**, 39,	4.8	17
169	Selective dopamine receptors: Synthesis, complexing properties, and molecular modelling studies of new podands derived from 4-hydroxy-1H-pyrazole. *Tetrahedron*, **1999**, 55, 2763-2772	2.4	17
168	Reaction of 4-hydrazinoquinolines with diketones. Synthesis and spectroscopy (1h, 13c nmr, ms) of some pyrazolylquinolines. *Journal of Heterocyclic Chemistry*, **1989**, 26, 733-738	1.9	17
167	Intranasal siRNA administration reveals IGF2 deficiency contributes to impaired cognition in Fragile X syndrome mice. *JCI Insight*, **2017**, 2, e91782	9.9	17
166	TDP-43: A Key Therapeutic Target beyond Amyotrophic Lateral Sclerosis. *ACS Chemical Neuroscience*, **2019**, 10, 1183-1196	5.7	17
165	Morphometric and neurochemical alterations found in l-BMAA treated rats. *Environmental Toxicology and Pharmacology*, **2015**, 39, 1232-45	5.8	16
164	Biology-oriented development of novel lipophilic antioxidants with neuroprotective activity. *RSC Advances*, **2015**, 5, 15800-15811	3.7	16
163	Crosstalk between phosphodiesterase 7 and glycogen synthase kinase-3: two relevant therapeutic targets for neurological disorders. *ACS Chemical Neuroscience*, **2014**, 5, 194-204	5.7	16
162	Semiempirical (AM1, PM3 and SAM1) calculations of the protonation enthalpies of proton sponges related to 1,8-diaminonaphthalene. Estimation of the aqueous basicity of new designed superbases. *Journal of the Chemical Society Perkin Transactions II*, **1995**, 923-927		16
161	Synthesis of [CH(CN)NH] pseudopeptides. A new peptide bond surrogate. *Tetrahedron Letters*, **1991**, 32, 7579-7582	2	16
160	On the Tautomerism of 2-Phenacyl-4-pyrimidinones and Related Compounds. *Chemische Berichte*, **1989**, 122, 919-924		16

159	A Triazolotriazine-Based Dual GSK-3β/CK-1δ Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic Inhibition. *ChemMedChem*, **2019**, 14, 310-314	3.7	16
158	Analysis of β-N-methylamino-L-alanine (L-BMAA) neurotoxicity in rat cerebellum. *NeuroToxicology*, **2015**, 48, 192-205	4.4	15
157	Modulation of GSK-3 provides cellular and functional neuroprotection in the rd10 mouse model of retinitis pigmentosa. *Molecular Neurodegeneration*, **2018**, 13, 19	19	15
156	Recapitulation of Pathological TDP-43 Features in Immortalized Lymphocytes from Sporadic ALS Patients. *Molecular Neurobiology*, **2019**, 56, 2424-2432	6.2	15
155	Anticonvulsant and neuroprotective effects of the novel calcium antagonist NP04634 on kainic acid-induced seizures in rats. *Journal of Neuroscience Research*, **2009**, 87, 3687-96	4.4	15
154	Synthesis and biological evaluation of tacrine-thiadiazolidinone hybrids as dual acetylcholinesterase inhibitors. *Archiv Der Pharmazie*, **2005**, 338, 18-23	4.3	15
153	The structure of the compounds resulting from the reaction of arylhydrazines with dehydroacetic acid: an NMR and crystallographic study. *Tetrahedron*, **1995**, 51, 4891-4906	2.4	15
152	Novel Curcumin-Diethyl Fumarate Hybrid as a Dualistic GSK-3β Inhibitor/Nrf2 Inducer for the Treatment of Parkinson's Disease. *ACS Chemical Neuroscience*, **2020**, 11, 2728-2740	5.7	15
151	Drugs in clinical development for the treatment of amyotrophic lateral sclerosis. *Expert Opinion on Investigational Drugs*, **2017**, 26, 403-414	5.9	14
150	A preliminary investigation of phoshodiesterase 7 inhibitor VP3.15 as therapeutic agent for the treatment of experimental autoimmune encephalomyelitis mice. *Journal of Chemical Neuroanatomy*, **2017**, 80, 27-36	3.2	14
149	Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents. *European Journal of Medicinal Chemistry*, **2017**, 138, 328-342	6.8	14
148	Regioselective lipase-catalyzed synthesis of l-glutamic β-monoamide derivatives. Effect of the N-blocking group. *Tetrahedron*, **1997**, 53, 11745-11752	2.4	14
147	Imidazothiadiazine dioxides: synthesis and antiviral activity. *Bioorganic and Medicinal Chemistry*, **1999**, 7, 1617-23	3.4	14
146	Synthesis and biological evaluation of 4-quinolone ribosides. *Journal of the Chemical Society Perkin Transactions 1*, **1993**, 845		14
145	Synthesis and spectroscopic properties of N-azolylpropanamides. *Journal of Heterocyclic Chemistry*, **1988**, 25, 225-229	1.9	14
144	Multitarget cannabinoids as novel strategy for Alzheimer disease. *Current Alzheimer Research*, **2013**, 10, 229-39	3	14
143	Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases. *European Journal of Medicinal Chemistry*, **2019**, 161, 39-47	6.8	14
142	A Focused Library of Psychotropic Analogues with Neuroprotective and Neuroregenerative Potential. *ACS Chemical Neuroscience*, **2019**, 10, 279-294	5.7	14

141	Small molecules targeting glycogen synthase kinase 3 as potential drug candidates for the treatment of retinitis pigmentosa. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2017**, 32, 522-526	5.6	13
140	Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. *European Journal of Medicinal Chemistry*, **2018**, 145, 431-444	6.8	13
139	Benzothiadiazine dioxide acyclonucleosides as lead compounds for the development of new agents against human cytomegalovirus and varicella-zoster virus infections. *Bioorganic and Medicinal Chemistry Letters*, **1997**, 7, 1031-1032	2.9	13
138	Dioxides of bicyclic thiadiazines: a new family of smooth muscle relaxants. *Bioorganic and Medicinal Chemistry*, **1995**, 3, 179-85	3.4	13
137	New 1,2,6-thiadiazine dioxide acyclonucleosides: synthesis and antiviral evaluation. *Bioorganic and Medicinal Chemistry*, **1995**, 3, 1527-35	3.4	13
136	Regioselective lipase-mediated acylation-deacylation in thiadiazine diacyclonucleosides.. *Tetrahedron*, **1994**, 50, 13865-13870	2.4	13
135	Enhancing cAMP Levels as Strategy for the Treatment of Neuropsychiatric Disorders. *Current Topics in Medicinal Chemistry*, **2016**, 16, 3527-3535	3	13
134	Targeting autophagy in disease: established and new strategies. *Autophagy*, **2021**, 1-23	10.2	13
133	Cyclic Nucleotide-Specific Phosphodiesterases as Potential Drug Targets for Anti-Leishmania Therapy. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	12
132	Applications of a statistical model to the analysis of the kinetic parameters in isothermal and non-isothermal crystallization of polymer blends based on PVDF. *Polymer*, **1997**, 38, 2741-2746	3.9	12
131	Synthesis and muscarinic activities of O-[(benzyl- or benzoyl-pyrazolyl)propynyl]-oximes of N-methylpiperidinone, 3-tropinone, and 3-quinuclidinone. *Bioorganic and Medicinal Chemistry*, **2003**, 11, 2263-8	3.4	12
130	Prediction of Drug Half-life Values of Antihistamines Based on the CODES/Neural Network Model. *QSAR and Combinatorial Science*, **2000**, 19, 448-454		12
129	Lipase-Mediated Acylation of Acyclonucleosides. Application to Novel Fluoroquinolone Derivatives. *Synthetic Communications*, **1991**, 21, 1477-1480	1.7	12
128	CB1 blockade potentiates down-regulation of lipogenic gene expression in perirenal adipose tissue in high carbohydrate diet-induced obesity. *PLoS ONE*, **2014**, 9, e90016	3.7	12
127	Indazolylketones as new multitarget cannabinoid drugs. *European Journal of Medicinal Chemistry*, **2019**, 166, 90-107	6.8	12
126	Dibenzo[1,4,5]thiadiazepine: a hardly-known heterocyclic system with neuroprotective properties of potential usefulness in the treatment of neurodegenerative diseases. *European Journal of Medicinal Chemistry*, **2014**, 81, 350-8	6.8	11
125	Synthesis of new N-(4-pyridyl)-1-aminopyrazoles and their muscarinic and adrenergic properties. *Archiv Der Pharmazie*, **2000**, 333, 118-22	4.3	11
124	Lipase-catalysed synthesis of new acetylcholinesterase inhibitors: N-benzylpiperidine aminoacid derivatives. *Bioorganic and Medicinal Chemistry*, **2000**, 8, 731-8	3.4	11

123	Hindered Inversion/Rotation in Diheteroaryl Alkyl Amines with a N-(1-Pyrazolyl) Group: Dynamic NMR and Molecular Modelling Studies. *Tetrahedron*, **2000**, 56, 1739-1743	2.4	11
122	On the tautomerism of 2,1,3-benzothiadiazinone S,S-dioxide and related compounds. *Tetrahedron*, **1999**, 55, 12405-12410	2.4	11
121	Intramolecular oxidative cyclizations in heteroarylthioureas: A versatile pathway to bridgehead heterocyclic systems. *Journal of Heterocyclic Chemistry*, **1999**, 36, 991-995	1.9	11
120	Application of ultrasonic nebulization for the determination of rare earth elements in phosphates and related sedimentary rocks using inductively coupled plasma atomic emission spectrometry with comments on dissolution procedures. *Journal of Analytical Atomic Spectrometry*, **1993**, 8, 833	3.7	11
119	Tautomerism of benzo- and cyclopenta-[1,2,6]thiadiazine S,S-dioxides. *Journal of the Chemical Society Perkin Transactions II*, **1994**, 1561-1564		11
118	Structure of 1,2,6-thiadiazine 1,1-dioxides. *Journal of Physical Organic Chemistry*, **1990**, 3, 470-476	2.1	11
117	Inhibition of hippocampal long-term potentiation by high-fat diets: is it related to an effect of palmitic acid involving glycogen synthase kinase-3?. *NeuroReport*, **2017**, 28, 354-359	1.7	10
116	Potential anti-Alzheimer effects of selected Lamiaceae plants through polypharmacology on glycogen synthase kinase-3, secretase, and casein kinase 1. *Industrial Crops and Products*, **2019**, 138, 111431	5.9	10
115	Impairments in cognition and neural precursor cell proliferation in mice expressing constitutively active glycogen synthase kinase-3. *Frontiers in Behavioral Neuroscience*, **2015**, 9, 55	3.5	10
114	Adiponectin promoter activator NP-1 reduces body weight and hepatic steatosis in high-fat diet-fed animals. *American Journal of Physiology - Endocrinology and Metabolism*, **2012**, 302, E817-30	6	10
113	Resolution of 1-(4-amino-3-chloro-5-cyanophenyl)-2-bromo-1-ethanol by lipase mediated enantioselective alcoholysis, hydrolysis and acylation. *Tetrahedron: Asymmetry*, **1998**, 9, 2229-2232		10
112	SO2 extrusion in 1,2,6-thiadiazine 1,1-dioxides: a novel synthesis of pyrazoles. *Canadian Journal of Chemistry*, **1993**, 71, 410-412	0.9	10
111	Small GSK-3 Inhibitor Shows Efficacy in a Motor Neuron Disease Murine Model Modulating Autophagy. *PLoS ONE*, **2016**, 11, e0162723	3.7	10
110	Pharmacological tools based on imidazole scaffold proved the utility of PDE10A inhibitors for Parkinson's disease. *Future Medicinal Chemistry*, **2017**, 9, 731-748	4.1	9
109	The new iminothiadiazole derivative VP1.14 ameliorates hippocampal damage after an excitotoxic injury. *Journal of Neurochemistry*, **2012**, 122, 1193-202	6	9
108	NP04634 prevents cell damage caused by calcium overload and mitochondrial disruption in bovine chromaffin cells. *European Journal of Pharmacology*, **2009**, 607, 47-53	5.3	9
107	Benzothiadiazine dioxide human cytomegalovirus inhibitors: synthesis and antiviral evaluation of main heterocycle modified derivatives. *Antiviral Chemistry and Chemotherapy*, **2003**, 14, 107-14	3.5	9
106	Chlorophenylmethyl benzothiadiazine dioxides derivatives: potent human cytomegalovirus inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **1999**, 9, 3133-6	2.9	9

105	Candida antarctica lipase B catalysed amidation of pyroglutamic acid derivatives. A reaction survey. *Journal of Molecular Catalysis B: Enzymatic*, **1999**, 7, 299-306		9
104	Regioselective Mucor miehei lipase catalyzed synthesis of podands containing a 1,3-bis(1H-Pyrazol-1-yl)propane unit. *Tetrahedron*, **1995**, 51, 2417-2426	2.4	9
103	Synthesis and NMR spectroscopy (1H 13C) of 1-(2?-benzothiazolyl)-3(5),4-polymethylenepyrazoles and related compounds. *Journal of Heterocyclic Chemistry*, **1991**, 28, 647-651	1.9	9
102	Synthesis of 2S-Dioxo Isosteres of Purine and Pyrimidine Nucleosides IV. Selective Glycosylation of 4-Amino-5H-Imidazo [4, 5-c]-1, 2, 6-Thiadiazine 2, 2-Dioxide. *Nucleosides, Nucleotides and Nucleic Acids*, **1987**, 6, 631-642	1.4	9
101	Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods. *Pharmaceuticals*, **2021**, 14,	5.2	9
100	Therapeutic potential of novel Cell Division Cycle Kinase 7 inhibitors on TDP-43-related pathogenesis such as Frontotemporal Lobar Degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). *Journal of Neurochemistry*, **2021**, 156, 379-390	6	9
99	Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis. *European Journal of Medicinal Chemistry*, **2021**, 210, 112968	6.8	9
98	Mitophagy Modulation, a New Player in the Race against ALS. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	9
97	Selective carriers of norepinephrine and ammonium ions: ionophoric properties and molecular modelling studies of diester crown compounds containing a 1,3-bis(1H-pyrazol-1-yl)propane unit. *Bioorganic and Medicinal Chemistry*, **1997**, 5, 363-71	3.4	8
96	Regioselective lipase-catalysed monoamidation of d-glutamic acid diesters: effect of the N-protecting group. *Tetrahedron: Asymmetry*, **2000**, 11, 2537-2545		8
95	Synthesis and intramolecular cyclization of bisthiadiazinylmethane derivatives. *Tetrahedron*, **1985**, 41, 3105-3116	2.4	8
94	Computer-aided molecular design of pyrazolotriazines targeting glycogen synthase kinase 3. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2019**, 34, 87-96	5.6	8
93	Insights into real-time chemical processes in a calcium sensor protein-directed dynamic library. *Nature Communications*, **2019**, 10, 2798	17.4	7
92	Serum- and glucocorticoid-induced kinase 1, a new therapeutic target for autophagy modulation in chronic diseases. *Expert Opinion on Therapeutic Targets*, **2020**, 24, 231-243	6.4	7
91	Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties. *European Journal of Medicinal Chemistry*, **2020**, 190, 112090	6.8	7
90	New applications for known drugs: Human glycogen synthase kinase 3 inhibitors as modulators of Aspergillus fumigatus growth. *European Journal of Medicinal Chemistry*, **2016**, 116, 281-289	6.8	7
89	Biological and Pharmacological Characterization of Benzothiazole-Based CK-1 Inhibitors in Models of Parkinson's Disease. *ACS Omega*, **2017**, 2, 5215-5220	3.9	7
88	Synthesis and Antiviral Activity of Modified 1,2,6-Thiadiazine Dioxide Acyclonucleosides. *Nucleosides & Nucleotides*, **1997**, 16, 265-276		7

87	Peripheral and dual binding site inhibitors of acetylcholinesterase as neurodegenerative disease modifying agents. *Expert Opinion on Therapeutic Patents*, **2003**, 13, 1725-1732	6.8	7
86	Novel agents for the treatment of human cytomegalovirus infection. *Expert Opinion on Therapeutic Patents*, **2000**, 10, 165-177	6.8	7
85	Rotational isomerism in 6-Ð-glucopyranosides of methyl-1,2,6-thiadiazin-3(2H)-one 1,1-dioxides. *Journal of the Chemical Society Perkin Transactions II*, **1990**, 783-786		7
84	New Synthetic Route to of 1,2,4-Thiadiazolines and 1,3-Thiazolines via Thiadiazolopyridinium Salts. *Heterocycles*, **1996**, 43, 2657	0.8	7
83	Towards discovery of new leishmanicidal scaffolds able to inhibit GSK-3. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2020**, 35, 199-210	5.6	7
82	Improved Controlled Release and Brain Penetration of the Small Molecule S14 Using PLGA Nanoparticles. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	7
81	Kinase Inhibitors as Underexplored Antiviral Agents. *Journal of Medicinal Chemistry*, **2021**,	8.3	7
80	Increasing Brain Permeability of PHA-767491, a Cell Division Cycle 7 Kinase Inhibitor, with Biodegradable Polymeric Nanoparticles. *Pharmaceutics*, **2021**, 13,	6.4	7
79	Identification of potential inhibitors of protein-protein interaction useful to fight against Ebola and other highly pathogenic viruses. *Antiviral Research*, **2021**, 186, 105011	10.8	7
78	1-Aryl-3-(4-methoxybenzyl)ureas as potentially irreversible glycogen synthase kinase 3 inhibitors: Synthesis and biological evaluation. *Bioorganic and Medicinal Chemistry Letters*, **2019**, 29, 1597-1600	2.9	6
77	Functionalized aromatic esters of the Amaryllidaceae alkaloid haemanthamine and their in vitro and in silico biological activity connected to Alzheimer's disease. *Bioorganic Chemistry*, **2020**, 100, 103928	5.1	6
76	Good oral absorption prediction on non-nucleoside benzothiadiazine dioxide human cytomegalovirus inhibitors using combined chromatographic and neuronal network techniques. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 1919-21	2.9	6
75	The Regio- and Stereocontrolled Ring Opening of Heteroarylglycidates with Nitrogen Nucleophiles. *Tetrahedron Letters*, **1995**, 36, 5417-5420	2	6
74	QSAR Modelling to Identify LRRK2 Inhibitors for Parkinson's Disease. *Journal of Integrative Bioinformatics*, **2019**, 16,	3.8	6
73	High-fructose corn syrup consumption in adolescent rats causes bipolar-like behavioural phenotype with hyperexcitability in hippocampal CA3-CA1 synapses. *British Journal of Pharmacology*, **2018**, 175, 4450-4463	8.6	6
72	Identification of Niemann-Pick C1 protein as a potential novel SARS-CoV-2 intracellular target. *Antiviral Research*, **2021**, 194, 105167	10.8	6
71	Deciphering the Inhibition of the Neuronal Calcium Sensor 1 and the Guanine Exchange Factor Ric8a with a Small Phenothiazine Molecule for the Rational Generation of Therapeutic Synapse Function Regulators. *Journal of Medicinal Chemistry*, **2018**, 61, 5910-5921	8.3	5
70	Targeting PDE10A GAF Domain with Small Molecules: A Way for Allosteric Modulation with Anti-Inflammatory Effects. *Molecules*, **2017**, 22,	4.8	5

69	Multitarget Drug Discovery for Alzheimer's Disease: Triazinones as BACE-1 and GSK-3 Inhibitors. *Angewandte Chemie*, **2015**, 127, 1598-1602	3.6	5
68	Lipase catalysed amidation of diethyl glutamate derivatives; peculiarities of ethyl S- and R-pyroglutamate. *Biotechnology Letters*, **1998**, 20, 261-263	3	5
67	Benzothiadiazine dioxides (BTD) derivatives as non-nucleoside human cytomegalovirus (HCMV) inhibitors. study of structural requirements for biological activity. *Bioorganic and Medicinal Chemistry*, **2003**, 11, 2395-402	3.4	5
66	Regioselective Lipase-Catalysed Amidation of Dicarboxylic N-Blocked Amino Acid Diesters Effect of the Side-Chain Length. *European Journal of Organic Chemistry*, **1999**, 1999, 2835-2839	3.2	5
65	Conformation and ortho steric effects in a series of 2-(pyrazol-1-yl)quinolines. *Journal of Heterocyclic Chemistry*, **1996**, 33, 323-326	1.9	5
64	(E)-1-alkyl-[2-(1H-azol-2-yl)vinyl]pyridinium salts: theoretical analysis, synthesis and evaluation of their interaction with choline acetyltransferase.. *Bioorganic and Medicinal Chemistry Letters*, **1992**, 2, 1493-1496	2.9	5
63	Synthesis and cytostatic screening of an SO2 analogue of doridosine. *Archiv Der Pharmazie*, **1988**, 321, 99-101	4.3	5
62	Peripheral and dual binding site inhibitors of acetylcholinesterase as neurodegenerative disease-modifying agents. *Expert Opinion on Therapeutic Patents*, **2003**, 13, 1725-1732	6.8	5
61	Thiadiazolopyridinium Salts: Intermediates for Heterocyclic Synthesis. *Heterocycles*, **1994**, 38, 1737	0.8	5
60	From simple quinoxalines to potent oxazolo[5,4-f]quinoxaline inhibitors of glycogen-synthase kinase 3 (GSK3). *Organic and Biomolecular Chemistry*, **2019**, 18, 154-162	3.9	5
59	Molecular Alterations in Sporadic and -ALS Immortalized Lymphocytes: Towards a Personalized Therapy. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	5
58	Theoretical and Experimental Approaches Aimed at Drug Design Targeting Neurodegenerative Diseases. *Processes*, **2019**, 7, 940	2.9	5
57	The adiponectin promoter activator NP-1 induces high levels of circulating TNF and weight loss in obese (fa/fa) Zucker rats. *Scientific Reports*, **2018**, 8, 9858	4.9	5
56	Tideglusib, a Non-ATP Competitive Inhibitor of GSK-3 as a Drug Candidate for the Treatment of Amyotrophic Lateral Sclerosis. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	5
55	Discovery of novel PDE4A inhibitors as potential agents against schistosomiasis. *Future Medicinal Chemistry*, **2019**, 11, 1703-1720	4.1	4
54	Unraveling phosphodiesterase surfaces. Identification of phosphodiesterase 7 allosteric modulation cavities. *European Journal of Medicinal Chemistry*, **2013**, 70, 781-8	6.8	4
53	Synthesis of nonsymmetrically 3,4-disubstituted 1,2,5-thiadiazole dioxides. *Journal of Heterocyclic Chemistry*, **1998**, 35, 297-300	1.9	4
52	3-Amino Pyrazoles as Potent and Selective Glycogen Kinase Synthase 3 (GSK-3) Inhibitors281-305		4

51	Anti-HIV-1 activity of benzothiadiazine dioxide. *Antiviral Chemistry and Chemotherapy*, **2001**, 12, 347-51	3.5	4
50	GSK-3 Inhibitors: From the ´Brain to the ´Retina and Back Again. *Advances in Experimental Medicine and Biology*, **2019**, 1185, 437-441	3.6	4
49	Benzothiazole-Based LRRK2 Inhibitors as Wnt Enhancers and Promoters of Oligodendrocytic Fate. *Journal of Medicinal Chemistry*, **2020**, 63, 2638-2655	8.3	4
48	Driving next-generation autophagy researchers towards translation (DRIVE), an international PhD training program on autophagy. *Autophagy*, **2019**, 15, 347-351	10.2	4
47	Protein kinase inhibitors for amyotrophic lateral sclerosis therapy. *British Journal of Pharmacology*, **2021**, 178, 1316-1335	8.6	4
46	QSAR Modelling for Drug Discovery: Predicting the Activity of LRRK2 Inhibitors for Parkinson Disease Using Cheminformatics Approaches. *Advances in Intelligent Systems and Computing*, **2019**, 63-70	0.4	3
45	3-(Benzyloxy)-1-(5-[F]fluoropentyl)-5-nitro-1H-indazole: a PET radiotracer to measure acetylcholinesterase in brain. *Future Medicinal Chemistry*, **2017**, 9, 983-994	4.1	3
44	Glycogen synthase kinase-3. *International Journal of Alzheimerjs Disease*, **2011**, 2011, 279234	3.7	3
43	Comparative Molecular Field Analysis (CoMFA) on [6] + [6] Fused Pyrazines with Nematocide Properties. *QSAR and Combinatorial Science*, **1997**, 16, 372-376		3
42	Base promoted transformation on thiadiazolopyridinium chlorides. *Journal of Heterocyclic Chemistry*, **1997**, 34, 337-340	1.9	3
41	AMPA glutamate receptors and neuropathic pain. *Mini-Reviews in Medicinal Chemistry*, **2003**, 3, 757-63	3.2	3
40	P4-428 TDZDS: GSK3 inhibitors as therapeutic agents for Alzheimer's disease and other tauopathies. *Neurobiology of Aging*, **2004**, 25, S596	5.6	3
39	Molecular mechanics description of cytosine energy and geometry using preliminary ab initio results. *Computational and Theoretical Chemistry*, **2005**, 729, 59-64		3
38	Thienothiadiazine 2,2-dioxide acyclonucleosides: synthesis and antiviral activity. *Antiviral Chemistry and Chemotherapy*, **2000**, 11, 221-30	3.5	3
37	N-Glucosyl-5-amino-4-carbamoyl- and 4-Ethoxycarbonylimidazoles as Potential Precursors of 4-Oxoimdazo[4,5-c]-1,2,6-thiadiazine 2,2-Dioxides. *Heterocycles*, **1986**, 24, 3451	0.8	3
36	CHAPTER 12:Phosphodiesterase Inhibitors as a New Therapeutic Approach for the Treatment of Parkinson Disease. *RSC Drug Discovery Series*, **2013**, 294-307	0.6	3
35	Cognitive enhancement, TAU phosphorylation reduction, and neuronal protection by the treatment of an LRRK2 inhibitor in a tauopathy mouse model. *Neurobiology of Aging*, **2020**, 96, 148-154	5.6	3
34	biological activity of Mill. infusion against amyloid -peptide-induced toxicity and inhibition of GSK-3, CK-1, and BACE-1 enzymes relevant to Alzheimer's disease. *Saudi Pharmaceutical Journal*, **2021**, 29, 236-243	4.4	3

33	Developing novel classes of protein kinase CK1inhibitors by fusing [1,2,4]triazole with different bicyclic heteroaromatic systems. *European Journal of Medicinal Chemistry*, **2021**, 216, 113331	6.8	3
32	Glycogen Synthase Kinase-3 Maleimide Inhibitors As Potential PET-Tracers for Imaging Alzheimer's Disease: C-Synthesis and Proof of Concept. *Journal of Medicinal Chemistry*, **2021**,	8.3	3
31	Therapeutic approaches for the future treatment of Fragile X. *Current Opinion in Behavioral Sciences*, **2015**, 4, 6-21	4	2
30	Molecular modeling of (E)-1-alkyl-4(3)-[2-(1H-azolyl)vinyl]-pyridinium salts and evaluation of their behavior towards choline acetyltransferase. *Bioorganic and Medicinal Chemistry*, **1997**, 5, 949-54	3.4	2
29	Regioselective lipase catalyzed synthesis of diester crowns. New asymmetric macrocycles containing a 1,3-bis(1H-pyrazol-1-yl)propane unit. *Tetrahedron*, **1997**, 53, 11481-11488	2.4	2
28	Enzymatic alcoholysis of SO2-uracil analog diacyclonucleosides. Long-distance effect of the substituents on the regioselectivity. *Journal of Molecular Catalysis B: Enzymatic*, **1998**, 4, 295-302		2
27	Electron correlated ab initio study of amino group flexibility for improvement of molecular mechanics simulations on nucleic acid conformations and interactions. *Journal of Biological Physics*, **2007**, 33, 499-514	1.6	2
26	Enantioselective LC/MS method for the determination of an antimalarial agent Fenozan B07 in dog plasma. *Chirality*, **2006**, 18, 297-305	2.1	2
25	TDZD's: Selective and ATP Noncompetitive Glycogen Synthase Kinase 3 Inhibitors257-280		2
24	Glycosides of Pyrido [2,3-c]-1,2,6-thiadiazine 2,2-Dioxides. *Nucleosides & Nucleotides*, **1990**, 9, 69-79		2
23	Synthesis of a Valuable Precursor for the Preparation of Novel Quinolone Glycosides. *Synlett*, **1990**, 1990, 753-754	2.2	2
22	TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy.. *Journal of Medicinal Chemistry*, **2022**,	8.3	2
21	Multitarget Hybrid Fasudil Derivatives as a New Approach to the Potential Treatment of Amyotrophic Lateral Sclerosis.. *Journal of Medicinal Chemistry*, **2022**,	8.3	2
20	Glycogen Synthase Kinase-3Expression and Phosphorylation in Peripheral Blood Mononuclear Cells of Patients with Amyotrophic Lateral Sclerosis. *British Journal of Medicine and Medical Research*, **2014**, 4, 263-271		2
19	Chapter 8:Medicinal Chemistry Strategies to Discover New Leishmanicidal Drugs. *RSC Drug Discovery Series*, **2017**, 153-178	0.6	2
18	GSK3 Inhibitor-Induced Dentinogenesis Using a Hydrogel. *Journal of Dental Research*, **2021**, 220345211080652		2
17	Structure-Based Design of Potent Selective Nanomolar Type-II Inhibitors of Glycogen Synthase Kinase-3*Journal of Medicinal Chemistry*, **2021**, 64, 1497-1509	8.3	2
16	From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Protein-Templated Synthesis. *Angewandte Chemie - International Edition*, **2021**, 60, 19344-19354	16.4	2

15	Synthesis of New N-(4-Pyridyl)-1-aminopyrazoles and Their Muscarinic and Adrenergic Properties **2000**, 333, 118		2
14	Naphthoquinone as a New Chemical Scaffold for Leishmanicidal Inhibitors of Leishmania GSK-3. *Biomedicines*, **2022**, 10, 1136	4.8	2
13	Deciphering the enzymatic target of a new family of antischistosomal agents bearing a quinazoline scaffold using complementary computational tools. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2020**, 35, 511-523	5.6	1
12	Towards lipophilic derivatives of S-adenosyl-L-methionine. *Journal of Heterocyclic Chemistry*, **1998**, 35, 727-730	1.9	1
11	Glycogen Synthase Kinase 3: A Target for Novel Mood Disorder Treatments125-154		1
10	Marine Compounds as a New Source for Glycogen Synthase Kinase 3 Inhibitors307-331		1
9	Studies on the reactivity of some N-aryl- and N-heteroaryl-N'-alkylthioureas towards electrophilic reagents. Synthesis of new N-pyridylthioureas and thiazolines mar. *Journal of Heterocyclic Chemistry*, **2001**, 38, 435-441	1.9	1
8	The molecular structure of 3(5)-methyl-4,5(3)-trimethylenepyrazole hydrochloride and its13C and15N NMR spectroscopy. *Journal of Crystallographic and Spectroscopic Research*, **1993**, 23, 961-965		1
7	Identification of NPC1 as a novel SARS-CoV-2 intracellular target		1
6	Small molecule inhibitors of mammalian GSK-3 promote in vitro plant cell reprogramming and somatic embryogenesis in crop and forest species. *Journal of Experimental Botany*, **2021**, 72, 7808-7825	7	1
5	The Crystal Structures of Glycogen Synthase Kinase 361-82		
4	GSK-3, a Key Player in Alzheimer's Disease105-124		
3	Protein Kinase Assays for Drug Discovery189-201		
2	CHAPTER 8:Protein Kinase Inhibitors for the Treatment of Multiple Sclerosis. *RSC Drug Discovery Series*, **2019**, 170-196	0.6	
1	From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Protein-Templated Synthesis. *Angewandte Chemie*, **2021**, 133, 19493-19503	3.6	